Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM ESTRBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $6.00 (from $8.00) while maintaining a Sector Perform rating. DEPO reported a 3Q top-line miss and another 2017E guidance step-down. Revenue came in at ~$95 million, below consensus of ~$99 million. Guidance was again lowered by $2030 million to... More
